Highlights - B2B business model with a profit-sharing arrangement - Strong Q3 results backed by growth in emerging markets; margins moderate - Regulatory compliance adds to elevated multiples Fosun Pharma-promoted Gland Pharma (CMP: Rs2,284, Mcap: Rs 37,302 crore) in its first quarterly result after the IPO posted a strong set of numbers. While this should dispel some doubts about the earnings consistency of this recently-listed entity, the street is brimming with a new set of concerns. We have taken closer look at some of these and...
Moneycontrol Pro Panorama | Are US and Indian markets decoupling?
Aug 8, 2022 / 05:36 PM IST
In today’s edition of Moneycontrol Pro Panorama: The oil breather, Titan’s lustre, the Eastern Window, populism’s price, power 'Panchamrit' and more
Read NowMoneycontrol Pro Weekender | Shaktikanta Das refuses to pivot
Aug 6, 2022 / 10:21 AM IST
A look at the current macro readings is enough for the RBI governor not to budge and dilute his ‘withdrawal of accommodation’ stance
Read NowTo read the full story, Subscribe to Moneycontrol PRO
Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience
Already a member? Sign in
Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to
Ad free experience
Experience a non-intrusive navigation and faster response in the ad free mode
Sharpest Opinions
Access to 230+ exclusive stories per month from our editorial and Experts
+
Have a Global edge with access to content from world renowned experts and journalist
Actionable Insights
Access to 40+ weekly investment ideas including 4 daily technical calls
Virtual Events
Exclusive access to live webinars from market experts on trading and investment strategies
Newsletters
Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.
Get upto 50% discount on limited period offers